{"entity":{"id":"helena-yu","kind":"person","name":"Helena A. Yu","aka":[],"tldr":"Mapped how EGFR-mutant lung cancers resist osimertinib and led the HER3-directed ADC trials that followed.","summary":"Helena A. Yu is a Medical Oncologist on the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center, specialising in EGFR-mutant lung cancer. She is known for mapping how EGFR-mutant lung cancers resist EGFR inhibitors such as osimertinib, including the T790M mutation and histological transformation, and for leading the HER3-directed antibody-drug conjugate trials that followed. Her selected papers analyse tumour specimens at the time of acquired resistance to EGFR inhibitors in 155 patients, and report HERTHENA-Lung01, a phase 2 trial of patritumab deruxtecan in EGFR-mutated lung cancer after prior therapy. She continues to study resistance mechanisms and ADCs in non-small-cell lung cancer.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/helena-yu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20HA%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","her3"],"drugs":["osimertinib","patritumab-deruxtecan"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Thoracic Oncology Service","institutionId":"mskcc","specialisms":["EGFR-mutant lung cancer","Resistance mechanisms","ADCs in lung cancer"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/helena-yu"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yu%20HA%5BAuthor%5D"}],"papers":[{"title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","journal":"Clinical Cancer Research","year":2013,"url":"https://doi.org/10.1158/1078-0432.CCR-12-2246","doi":"10.1158/1078-0432.CCR-12-2246"},{"title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.23.01476","doi":"10.1200/JCO.23.01476"}],"orcid":"0000-0002-0377-9510"},"route":"/people/helena-yu/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}]}}